Full-Time

Business Manager

Confirmed live in the last 24 hours

Viatris

Viatris

10,001+ employees

Global healthcare company providing medicines access

No salary listed

Senior

Manchester, UK

The job is focused on the Central and South Manchester area.

Category
Project Management
Business Development
Business & Strategy
Required Skills
Data Analysis
Requirements
  • Education to degree level preferred
  • Successful track record in a similar role with a commercial mindset
  • Excellent analytical skills and ability to identify / distil opportunities from complex sets of data
  • Strong Project Management and Presentation Skills
  • Full, clean driving licence
  • ABPI
Responsibilities
  • The Allergy, Dermatology & Women’s Health Business Manager role will have responsibility and accountability for the strategic and operational account management of the Viatris promoted products.
  • The Business Manager will need to ensure the delivery of agreed sales objectives and resulting sales growth within a defined geographical territory and distinct timelines, whilst adhering to the ABPI Code of Conduct.
  • The development of effective customer relationships with key stakeholders across both primary and secondary care will be a critical success factor.
  • Building key relationships with relevant stakeholders in target accounts and previous demonstratable experience of this are vital to his role.
  • Excellent analytical skills and the ability to identify and assess business opportunities from complex sets of data is required.
  • The formulation of strategic, robust account plans based on data, local NHS knowledge and insights is also fundamental.
  • The construction of joint customer plans in partnership with key stakeholders around a solution focused approach, is pivotal to ensure continued collaboration with key NHS stakeholders.

Viatris provides a wide range of healthcare products, focusing on both generic and brand-name medications to meet global health needs. Their extensive portfolio includes high-quality medicines that cater to various health conditions, from acute illnesses to chronic diseases. Viatris operates a global supply chain that ensures these medicines are accessible to patients when and where they need them. Unlike many competitors, Viatris combines the strengths of generics and brands, allowing them to address healthcare challenges more comprehensively. The company's goal is to empower individuals to lead healthier lives at every stage, aiming to reach as many patients as possible worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Viatris can leverage digital health trends to expand telemedicine and remote monitoring services.
  • The rise of value-based healthcare aligns with Viatris' focus on patient outcomes and cost-effectiveness.
  • Expansion in emerging markets offers Viatris opportunities to increase market presence and reach.

What critics are saying

  • Increased competition from low-cost generics could erode Viatris' market share.
  • Patent expirations in 2025 may lead to revenue loss from generic competition.
  • Ongoing opioid litigation could result in financial liabilities and reputational damage.

What makes Viatris unique

  • Viatris bridges the gap between generics and brands, offering a unique healthcare approach.
  • The company has a diverse portfolio, supplying medicines to 1 billion patients annually.
  • Viatris' global supply chain is designed to reach patients worldwide efficiently.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

PharmiWeb
May 7th, 2025
Viatris Announces Quarterly Dividend

PITTSBURGH, May 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025, to shareholders of record as of the close of business on May 23, 2025.About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris

PR Newswire
Mar 28th, 2025
Viatris To Report First Quarter 2025 Financial Results On May 8, 2025

PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 27th, 2025
Viatris Maintains Dividend Policy For 2025 And Announces Quarterly Dividend

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally